Fibroma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Fibroma}} | {{Fibroma}} | ||
{{CMG}}; {{AE}} {{Ammu}} | |||
==Overview== | |||
==Epidemiology and Demographics== | |||
===Prevalence=== | |||
===Incidence=== | |||
===Case Fatality Rate=== | |||
===Gender=== | |||
===Race=== | |||
===Developed Countries=== | |||
===Developing Countries=== | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 14:38, 23 February 2016
|
Fibroma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fibroma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Fibroma epidemiology and demographics |
|
Risk calculators and risk factors for Fibroma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]